Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 33,972 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Thursday, September 4, 2025
Mind-Body-Heart Connection: Anger and Stress Linked to Cardiovascular Events
Wednesday, October 2, 2024
Some Epilepsy Drugs Tied to Cardiovascular Events in Older People
With your chance of epilepsy and seizures post stroke make sure your competent? doctor is aware of this.
10% seizures post stroke (19 posts to April 2017)
5% epileptic seizures after stroke (10 posts to April 2021)
epileptic seizures (6 posts to December 2015)
post-stroke epilepsy (7 posts to December 2016)
Just maybe you want your doctor to try these solutions.
Cannabidiol May Reduce Seizures by Half in Hard-to-treat Epilepsy
Or maybe the nasal spray referred to in here:
Preventing Seizure-Caused Damage to the Brain
The answers are out there, does your doctor know about them?
Mozart may reduce seizure frequency in people with epilepsy
A dietary supplement dampens the brain hyperexcitability seen in seizures or epilepsy
The latest here:
Some Epilepsy Drugs Tied to Cardiovascular Events in Older People
Link likely due to enzyme-inducing antiseizure medications
by Sophie Putka, Enterprise & Investigative Writer, MedPage Today October 2, 2024
An association between epilepsy and cardiovascular events (CVEs) in older people was likely largely due to the use of enzyme-inducing antiseizure medications (EIASM), according to a prospective cohort study from Canada.
Among over 27,000 participants, new-onset CVEs were more likely in those with epilepsy than those without (adjusted OR 2.20, 95% CI 1.48-3.27), with the relative contribution to this association highest for "strong" EIASM use (24.6%), reported Mark Keezer, MD, PhD, of Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and colleagues in JAMA Neurology.
"Our study suggests that enzyme-inducing antiseizure medications increase the risk of cardiovascular events," Keezer told MedPage Today. "Future studies will need to study whether this should lead to screening for cardiovascular disease in certain people at greater risk. Our study may also provide healthcare professionals further justification for avoiding enzyme-inducing antiseizure medications, when clinically feasible."
There is a strong association between epilepsy and cardiovascular disease, at least partly because of the overlap in risk factors, Keezer and co-authors noted. Stroke can cause epilepsy, and even in populations without cerebrovascular disease, the risk of developing cardiovascular disease is high, they pointed out. Previous research has suggested that potential damage to the heart and coronary vasculature by repeat seizures may contribute to this connection, along with EIASM use.
For this study, Keezer and team used data from 27,230 participants in the ongoing Canadian Longitudinal Study on Aging (CLSA) with 6 years of follow-up from 2015 to 2021. The CLSA includes adults ages 45 to 85 and excludes residents of long-term care facilities and those with cognitive impairment, among others.
Participants were included in this analysis if they reported no previous history of CVEs (stroke, transient ischemic attack, or myocardial infarction) at baseline. Mean age was 62.3, 52.4% were women, and 94.4% were white. In total, 431 had a lifetime history of epilepsy. Of those included, 86% completed follow-up.
The primary outcome was new-onset CVEs over 6 years, and new-onset strokes, transient ischemic attacks, or myocardial infarctions separately were secondary outcomes. To understand how mediator variables influenced relationships between epilepsy and CVEs, the researchers ran mediation analyses for strong EIASM use, weak EIASM use, Framingham score, Physical Activity Scale for the Elderly (PASE) score, and waist-to-hip ratio.
"Strong EIASM use" included use of carbamazepine, phenytoin, phenobarbital, and primidone, while "weak EIASM use" included use of drugs like oxcarbazepine, eslicarbazepine, topiramate, and rufinamide. Of the CVEs, strong EIASM use appeared to have the largest effect on myocardial infarction, with a proportion-mediated value of 59.1%.
Apart from the mediating effect of strong EIASM use, "more than two-thirds of this association may be due to other factors, such as more prevalent [cardiovascular risk factors] or a direct effect of epilepsy on [cardiovascular disease]," Keezer and colleagues wrote. Weak EIASM use, PASE score, and waist-to-hip ratio also played a role, with proportion-mediated values of 4.0%, 3.3%, and 1.6%, respectively.
The authors noted that they were limited by self-reported data, and by potential effects of the 14% of participants lost to follow-up. They also did not differentiate between ischemic stroke and hemorrhagic stroke, and noted that participants may have begun or stopped EIASM during follow-up, but EIASM data were only available for baseline use.
-
Sophie Putka is an enterprise and investigative writer for MedPage Today. Her work has appeared in the Wall Street Journal, Discover, Business Insider, Inverse, Cannabis Wire, and more. She joined MedPage Today in August of 2021. Follow
Disclosures
Data/biospecimens for this study came from the Canadian Longitudinal Study on Aging, which is funded by the Government of Canada through the Canadian Institutes of Health Research and the Canada Foundation for Innovation.
Keezer reported financial relationships with UCB, Eisai, Jazz Pharmaceuticals, and Paladin.
Co-authors reported financial relationships with Fonds de Recherche du Québec-Santé Support, Xenon, Theravance, Novartis, Eisai, Angelini Pharma, LivAssured, UCB, Montreal Heart Institute, and Jazz Pharmaceuticals.
Primary Source
JAMA Neurology
Source Reference: Li J, et al "Antiseizure medications and cardiovascular events in older people with epilepsy" JAMA Neurol 2024; DOI: 10.1001/jamaneurol.2024.3210.
Saturday, February 10, 2024
Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial
Ask your doctor what this means for you.
Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial
BMJ 2023; 381 doi: https://doi.org/10.1136/bmj-2023-075230 (Published 28 June 2023)Cite this as: BMJ 2023;381:e075230
- Bridie Thompson, research officer1,
- Mary Waterhouse, statistician epidemiologist1,
- Dallas R English, professor2,
- Donald S McLeod, senior research officer1,
- Bruce K Armstrong, professor3,
- Catherine Baxter, project manager1,
- Briony Duarte Romero, research assistant1,
- Peter R Ebeling, professor4,
- Gunter Hartel, head of statistics5,
- , professor6,
- Sabbir T Rahman, research officer1,
- Jolieke C van der Pols, associate professor7,
- Alison J Venn, professor8,
- Penelope M Webb, professor1,
- David C Whiteman, professor1,
- Rachel E Neale, professor1
- Correspondence to: R Neale rachel.neale@qimrberghofer.edu.au
- Accepted 18 May 2023
Abstract
Objective
To investigate whether supplementing older adults with monthly doses of vitamin D alters the incidence of major cardiovascular events.
Main outcome measures
The main outcome for this analysis was the occurrence of a major cardiovascular event, including myocardial infarction, stroke, and coronary revascularisation, determined through linkage with administrative datasets. Each event was analysed separately as secondary outcomes. Flexible parametric survival models were used to estimate hazard ratios and 95% confidence intervals.
Results
21,302 people were included in the analysis. The median intervention period was five years. 1336 participants experienced a major cardiovascular event (placebo 699 (6.6%); vitamin D 637 (6.0%)). The rate of major cardiovascular events was lower in the vitamin D group than in the placebo group (hazard ratio 0.91, 95% confidence interval 0.81 to 1.01), especially among those who were taking cardiovascular drugs at baseline (0.84, 0.74 to 0.97; P for interaction=0.12), although the P value for interaction was not significant (<0.05). Overall, the difference in standardised cause specific cumulative incidence at five years was −5.8 events per 1000 participants (95% confidence interval −12.2 to 0.5 per 1000 participants), resulting in a number needed to treat to avoid one major cardiovascular event of 172. The rate of myocardial infarction (hazard ratio 0.81, 95% confidence interval 0.67 to 0.98) and coronary revascularisation (0.89, 0.78 to 1.01) was lower in the vitamin D group, but there was no difference in the rate of stroke (0.99, 0.80 to 1.23).
Meta-analyses of observational studies have found inverse associations between serum 25(OH)D concentration and risk of cardiovascular disease.56789 However, these findings might be due to reverse causality or uncontrolled confounding. Of three Mendelian randomisation studies, which largely overcome these biases, one reported an inverse association between genetically predicted 25(OH)D concentration up to 50 nmol/L and cardiovascular disease.10 The other studies found no association, but did not allow for nonlinear effects.1112 A meta-analysis of randomised controlled trials concluded that vitamin D supplementation does not prevent cardiovascular events.13 However, 45% of the 83 291 participants included in the meta-analysis were from the Women’s Health Initiative Trial, which was restricted to women, used a low dose of vitamin D, and had relatively low compliance.14 Cardiovascular disease was the primary outcome of the Vitamin D Assessment (ViDA) study15 and the Vitamin D and Omega 3 trial (VITAL).16 Despite different outcome definitions, both randomised controlled trials found that vitamin D supplementation had no effect on cardiovascular disease,1516 but VITAL excluded people with a history of cardiovascular disease and the ViDA study had relatively few events.
We launched the D-Health Trial to determine if monthly vitamin D supplementation can improve health outcomes in the older general population. It was a large intermittent dosing trial of vitamin D supplementation (n=21 315). Previous analysis of the D-Health cohort found that vitamin D supplementation did not reduce all cause mortality (the primary outcome of the overall trial) or mortality due to cardiovascular disease,17 but the effect on the incidence of major cardiovascular events has not been analysed.
For the current study we analysed data from the D-Health Trial to examine whether supplementing Australians aged ≥60 years with monthly doses of 60 000 IU of vitamin D altered the incidence of major cardiovascular events.